To test this hypothesis, we constructed gene-expression centroids for the different genomic subtypes and applied them to two independent breast cancer gene-expression data sets.
Recently, a combined tumour hypoxia, genomic instability and genomic subtype signature has demonstrated prognostic significance in men with PCa treated with external beam RT (Lalonde et al, 2014).
While the treatment of women with MBC will become even more complex as novel therapies emerge alongside of clinical decision-making tools that allow personalization of therapies according to molecular and genomic subtype, one basic principle ultimately will remain unchanged: do no harm.
In strong contrast, tumors of the luminal-simple genomic subtype displayed a stable genome without high-level amplifications and with CNAs primarily on chromosomes 1q and 16q.
Even in multivariate analysis, the genomic profile (the classification into genomic subtype) is still statistically significant and therefore provides useful additional prognostic information [ 40, 69].
We then performed genomic subtype analysis of all ACVR2 non expressing cancers and found that the lack of the chromosomal instability (CIN) phenotype correlated with ACVR2 promoter hypermethylation (Table 2), suggesting separate pathways for MSI-/LOH+ and MSI-/LOH colon cancers.
We also observed a significant difference in methylation when comparing node positive (49%) and node negative cases (38%), irrespective of genomic subtype.
High-density SNP array datasets for patient tumors and established cell lines were used to define genomic subclasses of the diseases and identify cell lines representative of each genomic subtype.
Tumors of the 1q/16q genomic subtype showed better disease-specific survival as compared with the amplifier and complex subtypes, whereas tumors with a basal-like gene-expression profile were found predominantly within the complex genomic subtype [ 3].
This genomic subtype is that of worst prognosis, consisting mainly of ER-/basal and ER+/luminal-B tumours.
